Jul 22, 2020

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2020 Annual Meeting on Women’s Cancer Webinar Series. Featuring perspectives from Drs Michael J Birrer, Ursula Matulonis, David M O’Malley and Krishnansu S Tewari.

• Molecular subtypes of endometrial cancer and response to immune checkpoint inhibitors; testing for mismatch repair deficiency and POLE mutations (00:00)
• Integration of immune checkpoint inhibitors into the management of endometrial cancer (10:31)
• Efficacy and tolerability of anti-PD-1/PD-L1 antibodies for endometrial cancer; incorporation of pembrolizumab/lenvatinib into the treatment algorithm (17:24)
• Activity of immune checkpoint inhibitors alone and in combination with chemotherapy for cervical cancer; results from the JAVELIN Ovarian 100 trial evaluating avelumab as first-line therapy for ovarian cancer (29:16)
• Role of immune checkpoint inhibitors in the first- and second-line settings for patients with metastatic cervical cancer; perspective on hyperprogression and pseudoprogression (40:38)
• Emerging data with immune checkpoint inhibitors in combination with chemotherapy or PARP inhibitors for ovarian cancer; recent guidelines regarding mismatch repair deficiency testing (53:07)
• Mechanism of action, dosing and ongoing evaluation of dostarlimab for advanced or recurrent endometrial cancer (57:07)
• Novel antibody-drug conjugate tisotumab vedotin under investigation for gynecologic cancers (1:02:55)
• Side effects associated with tisotumab vedotin (1:09:56)
• Challenges with immunotherapy for patients with gynecologic cancers in the COVID-19 era (1:16:20)
• Impact of COVID-19 on clinical research for patients with gynecologic cancers (1:22:13)

CME information and select publications